Expression and structure of interleukin 4 receptors in primary meningeal tumors

  title={Expression and structure of interleukin 4 receptors in primary meningeal tumors},
  author={Sachin Puri and Bharat H Joshi and Chitra Sarkar and Ashok Kumar Mahapatra and Ejaz Hussain and Subrata Sinha},
It was reported previously that malignant human tumors, like glioma and medulloblastoma, express high‐density interleukin (IL‐4) receptor mRNA and protein. Because IL‐4 receptors (R) are sensitive targets for targeted therapeutics, knowledge of the expression of these receptors in other central nervous system tumors is of great interest. In this study, the authors examined the expression and subunit composition of IL‐4R complex in primary human meningiomas. 
Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease
IL‐4Rα is overexpressed in human bladder cancer, which correlates with advanced grade and stage of the disease, and may be a bladder tumor‐associated protein and a prognostic biomarker.
The role and therapeutic potential of key molecules in the developmental pathways of meningiomas
Findings indicate no pathological overexpression of survivin in meningiomas as is evident in several other cancer types impeding apoptosis.
Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway
It is indicated that IL-13/IL-13Rα2 axis can mediate signal transduction in situ via AP-1 pathway in GBM and astrocytoma and may serve as a new target for GBM immunotherapy.
Molecular genetics of meningiomas: from basic research to potential clinical applications.
To review our current understanding of the molecular pathogenesis of meningiomas, to suggest topics for future investigations, and to present perspectives for clinical application. Significant
Brain Tumors and Inflammation
The role of inflammatory mediators and the inflammatory signaling cascades in cancers; recent advances in understanding the role ofinflammatory mediators in primary brain tumors; and current challenges impeding the therapeutic intervention in inflammatory pathways in brain cancer as well as the future prospects of immunotherapy in brain tumors are discussed.
Meningioma–Brain Crosstalk: A Scoping Review
It is unknown to what extent meningiomas elicit an immune response in the brain parenchyma, and it is speculated that tumour–brain crosstalk might only be relevant in cases of invasive menediomas that disrupt the pial–glial basement membrane.
Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways
IL4Rα and IL13Rα1 might be involved in the progression of RCC through JAK2/FOXO3 pathway, and their expression might be used as the novel prognostic factor and therapeutic target for RCC patients.
Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box.
Expression of IL4Rα and IL13Rα1 are associated with poor prognosis of soft-tissue sarcoma of the extremities, superficial trunk, and retroperitoneum
IL4Rα and IL13Rα1 are suggested to be associated with the progression of soft-tissue sarcoma, and the expression of IL4R α and IL14Rα2 might be novel prognostic indicators ofSoft-Tissue Sarcoma patients.
Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma
The findings suggest that diffusion and perfusion MRI techniques may be useful in evaluating early response to CED of MDNA55 in recurrent GBM patients.


Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.
  • R. Puri
  • Biology, Medicine
    Toxicologic pathology
  • 1999
Results indicate that localized administration can produce nontoxic levels of IL4-PE that may have significant activity against astrocytoma and in vivo experiments with nude mice have demonstrated that IL 4-PE has significant antitumor activity against human glioblastoma tumor model.
[Epidermal growth factor expression in brain neoplasms].
No correlation was found between expression of EGF and histopathological signs of tumour malignancy, although a tendency appeared towards a higher level of that factor in anaplastic tumours.
Expression and activation of epidermal growth factor receptors in meningiomas.
The concept that activation of EGFRs in human meningiomas by autocrine/paracrine stimulation may contribute to their proliferation is supported.
Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells.
These results establish uniform expression of IL-4R on head and neck cancer cell lines andIL-4 toxin IL4(38-37)-PE38KDEL as a novel therapeutic agent for the possible treatment of human head and head cancer.
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas.
These studies establish the IL-13Ralpha subunit as a novel tumor-specific protein that may be useful as a tumor marker, a target for cytotoxin/immunotoxin, or alternatively, a tumor-associated antigen for active, specific immunotherapy.
Interleukin-4-Pseudomonas Exotoxin Chimeric Fusion Protein for Malignant Glioma Therapy
Recombinant cpIL4-PE is a chimeric recombinant fusion protein consisting of a binding ligand, circularly permuted IL-4 and a mutated form of Pseudomonas exotoxin that can cause pronounced necrosis of recurrent glioma tumors without systemic toxicity.
Tumor antigens in astrocytic gliomas
The tumor‐specific nature of EGFRvIII combined with improved knowledge of immune mechanisms, especially in the context of the central nervous system, will facilitate the design of highly selective cell‐mediated therapeutic approaches with a view toward obtaining tumor‐ specific immunity.
IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein
The interleukin-4 receptor is established as a medulloblastoma-associated target for possible tumour-directed cancer therapy and sensitivity to cpIL4-PE is found to be highly and specifically cytotoxic to four of five medullOBlastoma cell lines.
Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
In an in vivo tumor model, downregulation of the GH/IGF-I axis significantly reduces meningioma growth and, in some instances, causes tumor regression.
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
The results show that human brain cancers richly express receptors for IL-13, and the interaction detected previously between receptors forIL-13 and IL-4 on solid tumors cell lines is of a qualitatively different character in U-251 MG and U-373 MG glioma cells.